International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefit in this indication.METHODS:We conducted a retrospective analysis of data from a French centralized referral treatment program and from the "LeishMan" European consortium database. All patients with parasitologically proven CL or MCL who received at least one dose of L-AmB were included. Positive outcome was based on ulcer closure as per recent WHO workshop guidelines.RESULTS:From 2008 through 2016, 43 travelers returning from 18 countries (Old World n = 28; New World n = 15) were analyzed with a median follow-up duration of 79 da...
species vary in sensitivity to available therapies. Fast and reliable molecular techniques have mad...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmani...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Lip...
Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We...
BackgroundLiposomal amphotericin B (L-AMB) has been used for mucosal leishmaniasis (ML), but compara...
Abstract INTRODUCTION: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. B...
Background: India is home to 60 % of the total global visceral leishmaniasis (VL) population. Use of...
Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
India is home to 60% of the total global visceral leishmaniasis (VL) population. Use of long-term or...
<div><p>Background</p><p>India is home to 60% of the total global visceral leishmaniasis (VL) popula...
species vary in sensitivity to available therapies. Fast and reliable molecular techniques have mad...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmani...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
International audienceBACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) oft...
Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Lip...
Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We...
BackgroundLiposomal amphotericin B (L-AMB) has been used for mucosal leishmaniasis (ML), but compara...
Abstract INTRODUCTION: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. B...
Background: India is home to 60 % of the total global visceral leishmaniasis (VL) population. Use of...
Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
India is home to 60% of the total global visceral leishmaniasis (VL) population. Use of long-term or...
<div><p>Background</p><p>India is home to 60% of the total global visceral leishmaniasis (VL) popula...
species vary in sensitivity to available therapies. Fast and reliable molecular techniques have mad...
International audienceBACKGROUND: Cutaneous leishmaniasis (CL) is a disfiguring but not life-threate...
Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmani...